降脂药物与两种骨骼疾病的因果关联:一项跨种族药物靶点孟德尔随机化分析

doi:10.6040/j.issn.1671-7554.0.2025.1276

摘要/Abstract

摘要： 目的采用药物靶点孟德尔随机化方法,评估他汀类药物、胆固醇吸收抑制剂、前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9, PCSK9)抑制剂、ATP-柠檬酸裂解酶(ATP citrate lyase, ACL)抑制剂和血管生成素样蛋白3(angiopoietin-like 3, ANGPTL3)抑制剂5类降脂药物与骨质疏松及骨关节炎发病风险的因果关联。方法利用公开发布的全基因组关联研究汇总数据,以5类降脂药物为暴露因素,骨质疏松和骨关节炎为结局变量,采用逆方差加权法为主、辅以7种补充方法进行药物靶点孟德尔随机化分析;采用错误发现率(false discovery rate, FDR)法校正多重比较,并通过异质性检验、多效性检验及留一法评估结果的稳健性。结果 PCSK9抑制剂的使用与骨质疏松风险增加呈正向因果关联,在欧洲人群(OR=1.169,95%CI:1.025~1.332,P_FDR=0.040)和东亚人群(OR=1.370,95%CI:1.115~1.683, P_FDR=0.008)中均有统计学意义;PCSK9抑制剂的使用与骨关节炎风险增加亦呈正向关联(OR=1.183,95%CI:1.102~1.271, P_FDR=1.46×10^-5)。他汀类药物的使用与骨关节炎的因果关联呈现人群异质性:在欧洲人群中呈正向关联(OR=1.128,95%CI:1.01~1.259, P_FDR=0.040),在东亚人群中呈负向关联(OR=0.440,95%CI:0.253~0.765, P_FDR=0.010)。胆固醇吸收抑制剂的使用与欧洲人群骨关节炎风险降低存在因果关联(OR=0.723,95%CI:0.544~0.962,P_FDR=0.043)。结论 PCSK9抑制剂的使用可增加欧亚人群的骨质疏松发病风险,而他汀类药物对骨关节炎的影响存在种族特异性,提示降脂药物的骨骼安全性评价需考虑靶点差异与人群异质性。

关键词: 孟德尔随机化, 前蛋白转化酶枯草溶菌素9抑制剂, 他汀类药物, 骨质疏松, 骨关节炎

Abstract: Objective To assess the causal associations of five lipid-lowering drug classes—statins, cholesterol absorption inhibitors, proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors, ATP citrate lyase(ACL)inhibitors, and angiopoietin-like 3(ANGPTL3)inhibitors—with the risk of osteoporosis and osteoarthritis using a drug-target Mendelian randomization approach. Methods Summary statistics from publicly available genome-wide association studies were used. Five lipid-lowering drug classes were considered as exposures, and osteoporosis and osteoarthritis as outcomes. Drug-target Mendelian randomization analyses were conducted using inverse-variance weighting as the primary method, supplemented by seven additional methods. The false discovery rate(FDR)method was applied to correct for multiple comparisons. Heterogeneity tests, pleiotropy tests, and leave-one-out analyses were performed to assess robustness. Results PCSK9 inhibitor use showed a positive causal association with increased osteoporosis risk in both European(OR=1.169, 95%CI: 1.025-1.332, P_FDR=0.040)and East Asian populations(OR=1.370, 95%CI: 1.115-1.683, P_FDR=0.008). PCSK9 inhibitor use was also positively associated with osteoarthritis risk in the European population(OR=1.183, 95%CI: 1.102-1.271, P_FDR=1.46×10^-5). The causal association between statin use and osteoarthritis exhibited population heterogeneity: a positive association in the European population(OR=1.128, 95%CI: 1.01-1.259, P_FDR=0.040)and a negative association in the East Asian population(OR=0.440, 95%CI: 0.253-0.765, P_FDR=0.010). Cholesterol absorption inhibitor use was causally associated with reduced osteoarthritis risk in the European population(OR=0.723, 95%CI: 0.544-0.962, P_FDR=0.043). Conclusion PCSK9 inhibitor use increases the risk of osteoporosis in both European and East Asian populations, while the effect of statins on osteoarthritis is population-specific. These findings suggest that skeletal safety evaluation of lipid-lowering drugs should consider target specificity and population heterogeneity.

Key words: Mendelian randomization, Proprotein convertase subtilisin/kexin type 9 inhibitors, Statins, Osteoporosis, Osteoarthritis

中图分类号:

R681

于皓瑞,陈昌海,张秀美,袁中尚. 降脂药物与两种骨骼疾病的因果关联:一项跨种族药物靶点孟德尔随机化分析[J]. 山东大学学报 (医学版), 2026, 64(6): 94-103.

YU Haorui, CHEN Changhai, ZHANG Xiumei, YUAN Zhongshang. Causal associations of lipid-lowering drugs with skeletal diseases: a transethnic drug-target Mendelian randomization analysis[J]. Journal of Shandong University (Health Sciences), 2026, 64(6): 94-103.

参考文献

[1] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14): 1671-1691. Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and treatment of primary osteoporosis(2022)[J]. Chinese General Practice, 2023, 26(14): 1671-1691.
[2] Kang J, Zhao SL, Wu XZ, et al. The association of lipid metabolism with bone metabolism and the role of human traits: a Mendelian randomization study[J]. Front Endocrinol, 2023, 14: 1271942. doi:10.3389/fendo.2023.1271942
[3] Funkhouser HL, Adera T, Adler RA. Effect of HMG-CoA reductase inhibitors(statins)on bone mineral density[J]. J Clin Densitom, 2002, 5(2): 151-158.
[4] Leutner M, Matzhold C, Bellach L, et al. Diagnosis of osteoporosis in statin-treated patients is dose-dependent[J]. Ann Rheum Dis, 2019, 78(12): 1706-1711.
[5] Lin TK, Chou P, Lin CH, et al. Long-term effect of statins on the risk of new-onset osteoporosis: a nation-wide population-based cohort study[J]. PLoS One, 2018, 13(5): e0196713. doi:10.1371/journal.pone.0196713
[6] Peña JM, Aspberg S, MacFadyen J, et al. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial[J]. JAMA Intern Med, 2015, 175(2): 171. doi:10.1001/jamainternmed.2014.6388
[7] Aikawa T. Geographic and ethnic variations in response to lipid-lowering therapies: why do they matter?[J]. Eur J Prev Cardiol, 2023, 30(11): 1118-1119.
[8] Lei SF, Chen Y, Xiong DH, et al. Ethnic difference in osteoporosis-related phenotypes and its potential underlying genetic determination[J]. J Musculoskelet Neuronal Interact, 2006, 6(1): 36-46.
[9] Schmidt AF, Finan C, Gordillo-Marañón M, et al. Genetic drug target validation using Mendelian randomization[J]. Nat Commun, 2020, 11: 3255. doi:10.1038/s41467-020-16969-0
[10] Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in genome-wide association studies of lipids[J]. Nature, 2021, 600(7890): 675-679.
[11] Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population[J]. Nature, 2023, 613(7944): 508-518.
[12] Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes[J]. Nat Genet, 2021, 53(10): 1415-1424.
[13] Tachmazidou I, Hatzikotoulas K, Southam L, et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data[J]. Nat Genet, 2019, 51(2): 230-236.
[14] Chen Z, Chen J, Collins R, et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up[J]. Int J Epidemiol, 2011, 40(6): 1652-1666.
[15] Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants[J]. Nat Genet, 2022, 54(12): 1803-1815.
[16] Matsunaga H, Ito K, Akiyama M, et al. Transethnic meta-analysis of genome-wide association studies identifies three new loci and characterizes population-specific differences for coronary artery disease[J]. Circ Genom Precis Med, 2020, 13(3): e002670. doi:10.1161/circgen.119.002670
[17] Swerdlow DI, Kuchenbaecker KB, Shah S, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies[J]. Int J Epidemiol, 2016, 45(5): 1600-1616.
[18] Kha HT, Basseri B, Shouhed D, et al. Oxysterols regulate differentiation of mesenchymal stem cells: pro-bone and anti-fat[J]. J Bone Miner Res, 2004, 19(5): 830-840.
[19] Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients[J]. Arterioscler Thromb Vasc Biol, 1997, 17(4): 680-687.
[20] Yang XL, Cui ZZ, Zhang H, et al. Causal link between lipid profile and bone mineral density: a Mendelian randomization study[J]. Bone, 2019, 127: 37-43. doi:10.1016/j.bone.2019.05.037
[21] Karasik D, Kiel DP. Evidence for pleiotropic factors in genetics of the musculoskeletal system[J]. Bone, 2010, 46(5): 1226-1237.
[22] Sabatine MS, Giugliano RP, Keech AC, et al. Evolo-cumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722.
[23] Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107.
[24] Huang L, Wu H, Wu Y, et al. Pcsk9 knockout aggravated experimental apical periodontitis via LDLR[J]. J Dent Res, 2022, 101(1): 83-92.
[25] Sun HL, Wu YR, Song FF, et al. Role of PCSK9 in the development of mouse periodontitis before and after treatment: a double-edged sword[J]. J Infect Dis, 2018, 217(4): 667-680.
[26] Zhang N, Zhang Y, Lin J, et al. Low-density lipoprotein receptor deficiency impaired mice osteoblastogenesis in vitro[J]. BioScience Trends, 2017, 11(6): 658-666.
[27] Sage AP, Lu JX, Atti E, et al. Hyperlipidemia induces resistance to PTH bone anabolism in mice via oxidized lipids[J]. J Bone Miner Res, 2011, 26(6): 1197-1206.
[28] Basiak M, Hachula M, Kosowski M, et al. The effect of PCSK9 inhibition on the stabilization of atherosclerotic plaque determined by biochemical and diagnostic imaging methods[J]. Molecules, 2023, 28(15): 5928. doi:10.3390/molecules28155928
[29] Zhang Y, Luo JN, Weng QY, et al. Ezetimibe prevents IL-1β-induced inflammatory reaction in mouse chondrocytes via modulating NF-κB and Nrf2/HO-1 signaling crosstalk[J]. Curr Pharm Biotechnol, 2022, 23(14): 1772-1780.
[30] Fraunberger P, Gröne E, Gröne HJ, et al. Ezetimibe reduces cholesterol content and NF-κB activation in liver but not in intestinal tissue in guinea pigs[J]. J Inflamm, 2017, 14: 3. doi:10.1186/s12950-017-0150-y
[31] Zhang Z, Deng CB, Ma X, et al. The association between statin use and osteoarthritis-related outcomes: an updated systematic review and meta-analysis[J]. Front Pharmacol, 2022, 13: 1003370. doi:10.3389/fphar.2022.1003370
[32] Wang J, Dong J, Yang J, et al. Association between statin use and incidence or progression of osteoarthritis: meta-analysis of observational studies[J]. Osteoarthr Cartil, 2020, 28(9): 1170-1179.
[33] Ramsey LB, Johnson SG, Caudle KE, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update[J]. Clin Pharmacol Ther, 2014, 96(4): 423-428. doi:10.1038/clpt.2014.125
[34] Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy: a genome-wide study[J]. N Engl J Med, 2008, 359(8): 789-799.
[35] Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin[J]. J Atheroscler Thromb, 2017, 24(1): 19-25.
[36] Tomlinson B, Chan P, Liu ZM. Statin intolerance: an Asian perspective[J]. J Atheroscler Thromb, 2020, 27(5): 485-488.
[37] Song GL, Lu YY. Association between the dietary inflammatory index and all-cause mortality in osteoarthritis[J]. BMC Musculoskelet Disord, 2024, 25(1): 407. doi:10.1186/s12891-024-07506-x
[38] Boer CG, Hatzikotoulas K, Southam L, et al. Deciphering osteoarthritis genetics across 826, 690 individuals from 9 populations[J]. Cell, 2021, 184(24): 6003-6005.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed